Trials / Completed

CompletedNCT00743015

Relative Bioavailability of a Single Dose of BI 44370 Tablet During and Between Migraine Attacks

Relative Bioavailability Following Single Oral Administration of 200 mg of BI 44370 During and Between Migraine Attacks in Male and Female Migraine Patients. An Open-label, Fixed-sequence, Two-period Study With Intraindividual Comparison

Status: Completed
Phase: Phase 1
Study type: Interventional
Enrollment: 19 (actual)

Sponsor: Boehringer Ingelheim · Industry
Sex: All
Age: 18 Years – 65 Years
Healthy volunteers: Not accepted

Summary

The general aim is to evaluate the relative oral bioavailability of BI 44370 TA tablets during and between migraine attacks as well as Safety, Tolerability and Pharmacokinetic

Conditions

Migraine Disorders

Interventions

Type	Name	Description
DRUG	BI 44370 TA tablet

Timeline

Start date: 2008-09-01
Primary completion: 2009-03-01
First posted: 2008-08-28
Last updated: 2013-11-01

Locations

2 sites across 2 countries: Belgium, Germany

Source: ClinicalTrials.gov record NCT00743015. Inclusion in this directory is not an endorsement.